FOCUS Study Shows MammaPrint Accurately Identifies Extremely Indolent Cancers
Findings confirm subanalysis of STO-3 trial and provide foundation for Read More
Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
Co-development program will utilize next-generation digital pathology platform and AI-based Read More
Agendia to Showcase Robust Clinical Research at SABCS 2020 Emphasizing Need for Diversity of Data to Treat Breast Cancer Patients
Variety of data confirm the importance of applying genomic analysis Read More
Agendia to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Agendia Co-Founder Named to Eighth Annual OncLive® Giants of Cancer Care® Class of Inductees
Laura van ’t Veer among 15 trailblazers in oncology honored Read More
MammaPrint® Approved for Reimbursement in Germany
IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ -- Agendia Inc., a world leader in Read More
Agendia to Participate in Stifel 2020 Virtual Healthcare Conference
Irvine, Calif., October 15, 2020 – Agendia, Inc., a world Read More
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
IRVINE, CALIF., U.S – 6 October 2020 – Agendia Inc., Read More
Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation
I AM HERE: An Intimate Portrait Series launches today Irvine, Read More
Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
Irvine, California – September 17, 2020 – Agendia, Inc., a Read More
